每经AI快讯，海翔药业（SZ 002099，收盘价：6.31元）11月18日晚间发布公告称，公司第八届第一次 董事会临时会议于2025年11月18日在公司会议室召开。会议审议了《关于聘任公司总经理的议案》等文 件。 每经头条（nbdtoutiao）——段睿：我与蔡磊是 "找钥匙的人"，纵使生前寻不到，也要为其他渐冻症患 者铺就近路 （记者 王晓波） 2025年1至6月份，海翔药业的营业收入构成为：医药制造业占比65.89%，染料行业占比33.09%，其他 占比1.02%。 截至发稿，海翔药业市值为102亿元。 ...

Core Viewpoint - Hualan Biological Engineering Co., Ltd. (SZ 301093) announced an investor meeting on November 18, 2025, where the company's Vice General Manager and Board Secretary Liu Xue participated in addressing investor inquiries [1] Financial Performance - For the first half of 2025, Hualan's revenue composition was 99.07% from the pharmaceutical manufacturing sector and 0.93% from other businesses [1] - As of the report date, Hualan's market capitalization stood at 7.7 billion yuan [1]

这一转变的核心逻辑在于资本的价值发现功能。 当A股市场因投资者情绪或流动性因素导致估值偏离基本面，股价估值明显低于内在价值时，国际资本 与长期资金却能够认识到上市公司的发展潜力，并通过港股市场进行买入并持有，从而推动估值回归理 性。 对比去年同期来看，AH股溢价出现明显收窄，目前也有宁德时代、招商银行、恒瑞医药、美的集团等 多股出现了AH股溢价倒挂的现象，这是中国优质资产受到国际资本青睐的结果，同时也是南向资金的 理性选择。未来不排除有更多两地上市公司的港股股价超越A股的可能。 过去，AH股溢价长期存在，主要源于两地市场流动性差异、投资者结构分化等原因。A股市场以散户 为主，流动性充沛且风险偏好较高，推动估值中枢上移；而港股市场机构投资者占比更高，定价更趋理 性，于是H股估值通常都会较A股更低。然而，这一格局在今年发生了显著变化：国际资本对中国优质 资产的配置需求上升，叠加南向资金持续流入，港股市场的流动性与估值水平逐渐提升，部分上市公司 的H股股价开始反超A股股价。 AH股溢价倒挂的直接原因是国际资本的重点青睐。随着全球资产配置向新兴市场倾斜，中国优质资产 因其稳定的基本面与成长性成为重点买入对象。外资机构 ...

Group 1 - The core point of the news is the retirement of Ms. Pinxiang Yu, the director and CEO of Hanyu Pharmaceutical, effective November 14, 2025, due to reaching retirement age [1] - After her retirement, Ms. Pinxiang Yu will no longer hold any positions within the company or its subsidiaries [1] - For the first half of 2025, Hanyu Pharmaceutical's revenue is entirely derived from the pharmaceutical manufacturing sector, accounting for 100% of its business [1] Group 2 - As of the report, Hanyu Pharmaceutical has a market capitalization of 17.1 billion yuan [2]

Company Overview - *ST Sailong (SZ 002898) announced the resignation of Ms. Tan Haiyan as the securities affairs representative due to personal career development reasons. After her resignation, she will no longer hold any positions in the company or its subsidiaries [1] Financial Performance - For the first half of 2025, *ST Sailong's revenue composition is as follows: pharmaceutical manufacturing accounts for 59.82%, the electronics industry accounts for 39.78%, and other businesses account for 0.4% [1] - As of the report date, *ST Sailong has a market capitalization of 2.4 billion yuan [1]

Group 1 - The core technical personnel, Mr. Le Jiamin, has applied for resignation due to age and health reasons, and has completed the departure procedures, no longer holding any position in the company [1] - For the fiscal year 2024, the revenue composition of the company is as follows: 99.67% from the pharmaceutical manufacturing industry and 0.33% from other businesses [1] - The current market capitalization of the company is 2.9 billion yuan [1]

Core Viewpoint - The company has been recognized as a quality management benchmark in Guangxi for its "Practice of Granule Quality Control Team Building Experience," highlighting its commitment to quality management and operational excellence [1][6]. Group 1: Recognition and Achievements - The company successfully entered the 2025 Guangxi Industrial Enterprise Quality Management Benchmark list, receiving formal recognition and a plaque from the Guangxi Industrial and Information Technology Department [1]. - This recognition follows the team's previous achievement of the "National Worker Pioneer" title in 2023, showcasing the effectiveness of its quality management practices [7]. Group 2: Quality Management Practices - The granule production team operates under a "Precision, Standardization, and Refinement" GMP management system, aiming for zero defects through strict adherence to quality standards [6]. - The team has achieved a 100% training qualification rate for all employees, enhancing their technical skills and quality awareness [6]. - The team maintains quality standards that exceed national regulations, with moisture content controlled below 2% compared to the national standard of ≤8% [7]. Group 3: Future Plans and Goals - The company plans to leverage this recognition to further promote the granule production team's practices across all departments, aiming for higher standards in quality control and innovation [7]. - The company is committed to contributing to the high-quality development of Guangxi's industry by enhancing product and service quality [7].

Group 1 - The core point of the article is that *ST Sailong has received approval from the National Medical Products Administration for its injectable Nicorandil product, which is a significant development for the company [1] - As of January to June 2025, *ST Sailong's revenue composition is as follows: 59.82% from the pharmaceutical manufacturing sector, 39.78% from the electronics sector, and 0.4% from other businesses [1] - The current market capitalization of *ST Sailong is 2.3 billion yuan [1]

Group 1 - The core point of the article is that Borui Pharmaceutical (SH 688166) held its 15th meeting of the 4th Board of Directors on November 13, 2025, to review proposals related to external investments and related transactions [1] - For the year 2024, Borui Pharmaceutical's revenue composition is 97.33% from the pharmaceutical manufacturing industry and 2.67% from other businesses [1] - As of the report date, Borui Pharmaceutical has a market capitalization of 23.2 billion yuan [1]

Core Viewpoint - The average stock price of A-shares is 13.92 yuan, with 20 stocks priced below 2 yuan, the lowest being *ST Yuan Cheng at 0.58 yuan [1] Stock Price Distribution - As of November 14, the Shanghai Composite Index closed at 3990.49 points, with a relatively small proportion of high-priced and low-priced stocks in the A-share market [1] - Among the low-priced stocks, 8 are ST stocks, accounting for 40% of those priced below 2 yuan [1] Market Performance - Out of the low-priced stocks, 18 saw an increase today, with notable gains from Rongsheng Development (10.17%), Yongtai Energy (9.82%), and *ST Jinke (4.76%) [1] Low-Priced Stock Rankings - The table lists various low-priced stocks, including their latest closing prices, daily price changes, turnover rates, price-to-book ratios, and industries [1] - For example, *ST Yuan Cheng has a closing price of 0.58 yuan, while *ST Suwu and *ST Jinke are at 0.97 yuan and 1.54 yuan respectively [1]